remitió Ruben Piacentini
Twonewantiviralmedications, ritonavir-boostednirmatrelvir (Paxlovid, ie, nirmatrelvir-ritonavir) and molnupiravir (Lagevrio), are currently available in theUS underemergency useauthorization. These 2 drugs areauthorized for treatmentofpatientswithmild tomoderateCOVID 19 who are not currently hospitalized but are at high risk of develop ingseveredisease.Nirmatrelvir-ritonavirandmolnupiravirareapproved for use only within 5 days of onset of COVID-19 symptoms.
Nirmatrelvir-ritonavir andmolnupiravir should be considered for patients with symptoms of COVID-19 who test positive for SARS CoV-2 and either are an older adult (aged 65 years or older) or are aged 12 years or older with an underlying condition that increases risk of severe outcomes of COVID-19 (such as cancer, heart disease, diabetes, and obesity). Read more…